This viewpoint discusses how international reference pricing affects drug costs for consumers and manufacturers under Medicare and Medicaid, suggesting implications for policy.
This Viewpoint discusses 3 US Centers for Medicare & Medicaid Services (CMS) drug pricing models and how a pivot toward international reference pricing could affect consumers, manufacturers, and drug pricing policy.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: